Pressure Ulcer Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Drugs Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight

Pressure Ulcer Treatment Market

(Albany, USA) DelveInsight’s ” Pressure Ulcer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Pressure Ulcer, historical and forecasted epidemiology as well as the Pressure Ulcer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

To strategically aid Pressure Ulcer companies developing drugs for Pressure Ulcer, DelveInsight launched a report titled as “Pressure Ulcer Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Pressure Ulcer market.

Get a free sample of “Pressure Ulcer Market Report”

Pressure Ulcer Market Report’s Key Highlights:

• Pressure Ulcer market is expected to grow at a decent CAduring the study period in 7MM.
• Key Pressure Ulcer Companies: Phagelux, MiMedx, EyeGene, Shionogi, NovaLead Pharma, Smith & Nephew PLC, Integra LifeSciences Holding Corporation, Baxter International Inc. (Hill-Rom Holdings Inc.), Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen AG, ConvaTec Group PLC, Coloplast Group, and others.
• Promising pressure ulcer therapies are SR-0379, EGT 022, GM-XANTHO, others.
• The incidence of Pressure Ulcers is more in patients who are previously suffering from Diabetes.
• The prevalence of diabetes in the 7MM was estimated to be 537 million cases in adults, out of which around 150 million suffer from ulcers at some point.
• According to the studies it is estimated that in the United States 10% of the people experience Ulcers at some point in their lifetime.
• The Pressure Ulcermarket is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various Pressure Ulcer pipeline products will significantly revolutionize the Pressure Ulcer market dynamics
• In October 2024, Imbed Biosciences announces U.S. Food and Drug Administration 510(k) clearance to market Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing to integrate lidocaine for the management of painful skin wounds. Microlyte® Ag/Lidocaine utilizes Imbed’s patented synthetic matrix to deliver ionic and metallic silver alongside lidocaine, providing both antimicrobial protection and local anesthetic effects. The dressing releases 40mg of lidocaine hydrochloride USP per 100cm² of wound surface area, equivalent to a 4% w/w gel. The advanced Microlyte® Ag/Lidocaine wound dressing is indicated for the management of a variety of partial- and full-thickness wounds under the supervision of a healthcare professional, including venous stasis ulcers, pressure sores, ischemic ulcers, partial thickness burns, donor site wounds, surgical wounds, post-surgical incisions, abrasions and lacerations.
• In July 2024, Xantho Biotechnology has announced results of a Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO in Pressure Ulcer Patients

Pressure Ulcer Country based Treatment Analysis:

The Pressure Ulcer treatment market report provides treatment regimen across the 7MM. It will help companies to analyse the practices followed across 7MM, patient journey and advances in Pressure Ulcer Therapies that have the potential to transform treatment paradigms and improve patient outcomes.

Pressure ulcers, also known as bedsores or pressure sores, are localized injuries to the skin and/or underlying tissue due to prolonged pressure on the skin. They commonly develop in individuals who are bedridden, use a wheelchair, or have limited mobility. These ulcers usually form over bony prominences, such as the heels, hips, tailbone, and elbows.

The development of pressure ulcers is influenced by various factors, including pressure intensity, duration, and the individual’s overall health. Reduced blood flow to the affected area leads to tissue damage, causing pain, open wounds, and sometimes severe complications like infections or tissue necrosis.

Preventing pressure ulcers involves regular repositioning, maintaining proper nutrition, using specialized support surfaces, and ensuring good skincare. Early detection and appropriate management are crucial to prevent their progression and promote healing. Healthcare professionals provide tailored treatments, including wound care, infection control, and pressure redistribution strategies, to manage pressure ulcers effectively.

Download the report to understand which factors are driving Pressure Ulcer epidemiology trends @ Pressure Ulcer Epidemiology Forecast

Pressure Ulcer Epidemiology Insights:

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Pressure Ulcer. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools. The epidemiology in report is segmented as:

Pressure Ulcer Epidemiology Segmentation:

• Total Prevalence of Pressure Ulcer
• Prevalent Cases of Pressure Ulcer by severity
• Gender-specific Prevalence of Pressure Ulcer
• Diagnosed Cases of Episodic and Chronic Pressure Ulcer

Pressure Ulcer Companies and Therapies:

EGT 022: EyeGene

EGT 022 is a RGD motif containing recombinant polypeptide from human-derived protein ADAM-15. It is being developed by EyeGene Inc.

And Many Others.

Emerging Pressure Ulcer drugs Uptake:

• In October 2024, Imbed Biosciences announces U.S. Food and Drug Administration 510(k) clearance to market Microlyte® Ag/Lidocaine, the first antimicrobial wound dressing to integrate lidocaine for the management of painful skin wounds. Microlyte® Ag/Lidocaine utilizes Imbed’s patented synthetic matrix to deliver ionic and metallic silver alongside lidocaine, providing both antimicrobial protection and local anesthetic effects. The dressing releases 40mg of lidocaine hydrochloride USP per 100cm² of wound surface area, equivalent to a 4% w/w gel. The advanced Microlyte® Ag/Lidocaine wound dressing is indicated for the management of a variety of partial- and full-thickness wounds under the supervision of a healthcare professional, including venous stasis ulcers, pressure sores, ischemic ulcers, partial thickness burns, donor site wounds, surgical wounds, post-surgical incisions, abrasions and lacerations.
• In July 2024, Xantho Biotechnology has announced results of a Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO in Pressure Ulcer Patients
• In March 2021, Smith+Nephew announced the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped significantly reduce dressing change frequency and weekly dressing costs while improving treatment satisfaction for clinicians and patients in a community setting.
• In February 2021, Axis Biosolutions received European CE mark approval for the advanced wound care product, MAxiCel, which is used in several chronic wounds, including pressure ulcers.

To know more about Pressure Ulcer companies working in the treatment market, visit @ Pressure Ulcer Clinical Trials and Therapeutic Assessment

Pressure Ulcer Market Forecast:

• The research includes a thorough analysis of the past and projected markets for Pressure Ulcer, which includes pharmacological outreach in the 7MM nations.
• The dynamics of the Pressure ulcer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Thymosin Beta 4, Ibuprofen, and others during the forecasted period 2019-2032.
• Rising prevalence, increasing prevalence, less competition for upcoming therapies and Companies shifting their focus to this area, despite low awareness of the disease are fuelling the Pressure Ulcer Market.

Discover more about therapies set to grab major Pressure Ulcer market share @ Pressure Ulcer Treatment Market

Scope of the Pressure Ulcer Market Report:

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Key Companies: Phagelux, MiMedx, EyeGene, Shionogi, NovaLead Pharma, Smith & Nephew PLC, Integra LifeSciences Holding Corporation, Baxter International Inc. (Hill-Rom Holdings Inc.), Molnlycke Health Care AB, Cardinal Health, Essity Aktiebolag, 3M Company, B. Braun Melsungen AG, ConvaTec Group PLC, Coloplast Group, and others.

Request for Sample Report @ https://www.delveinsight.com/sample-request/pressure-ulcers-market

DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Pressure Ulcer market landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the Pressure Ulcer market, including the competitive environment, key companies developing drugs for Pressure Ulcer, and their strategies. By analyzing Pressure Ulcer market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analysing Pressure Ulcer epidemiological trends, country wise patient journeys and existing treatment practices can helps in identifying gaps and opportunities within the Pressure Ulcer market. This involves recognizing areas where current Pressure Ulcer treatments may be insufficient or where there is an unmet need. The Pressure Ulcer market report is curated by taking account of various KOLs dealing with Pressure Ulcer. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific Pressure Ulcer market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing – reimbursement strategies, partnerships, or other strategic moves. Understanding the Pressure Ulcer market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading Pressure Ulcer companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Pressure Ulcer market with clarity and purpose.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting